Roelof Botha Sells 87,473 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) Director Roelof Botha sold 87,473 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $169.12, for a total transaction of $14,793,433.76. Following the sale, the director now owns 1,224,787 shares in the company, valued at approximately $207,135,977.44. This trade represents a 6.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Natera Stock Performance

Shares of NTRA stock traded up $4.83 during trading hours on Wednesday, reaching $174.00. 1,039,899 shares of the company’s stock were exchanged, compared to its average volume of 1,340,584. Natera, Inc. has a fifty-two week low of $55.56 and a fifty-two week high of $174.15. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $22.97 billion, a P/E ratio of -96.12 and a beta of 1.63. The business has a fifty day moving average price of $137.36 and a 200-day moving average price of $121.28.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. The firm had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business’s revenue for the quarter was up 63.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.95) earnings per share. Analysts predict that Natera, Inc. will post -1.66 EPS for the current fiscal year.

Hedge Funds Weigh In On Natera

Large investors have recently modified their holdings of the stock. Itau Unibanco Holding S.A. bought a new position in Natera in the second quarter valued at about $28,000. Quarry LP boosted its stake in shares of Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after buying an additional 108 shares during the period. Covestor Ltd lifted its holdings in Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares during the period. Finally, True Wealth Design LLC bought a new position in Natera in the third quarter valued at approximately $57,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on NTRA. The Goldman Sachs Group increased their price target on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. TD Cowen increased their price objective on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. UBS Group reduced their target price on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Finally, Canaccord Genuity Group raised their price target on shares of Natera from $150.00 to $165.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $140.59.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.